Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
SPDR S&P Biotech ETF Options Spot-On: On September 18th, 131.66K Contracts Were Traded, With 933.6K Open Interest
On September 18th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 131.66K options for the day, of which put options accounted for 31.04% of the total
SPDR S&P Biotech ETF Options Spot-On: On September 17th, 82,840 Contracts Were Traded, With 904.7K Open Interest
On September 17th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 82,840 options for the day, of which put options accounted for 33.05% of the total
SPDR S&P Biotech ETF Options Spot-On: On September 13th, 100.9K Contracts Were Traded, With 867.18K Open Interest
On September 13th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 100.9K options for the day, of which put options accounted for 56.66% of the total
These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.
Two major heavyweight events, "interest rate cuts + elections", have struck suddenly! Can the US stock market break the century-old curse of "September Hex"?
Since 1990, the average September decline of the S&P 500 index is 1.04%, with only a 47% chance of closing higher, performing far worse than other months.